BioPharma

BostonGene’s cloud-based platform integrates multiple AI-based molecular and immune profiling techniques that comprehensively analyze the tumor, microenvironment, and host immunity, uncovering treatable targets to personalize therapy for patients. Benefit from fast, accurate results in a CLIA-certified, CAP-accredited, and New York State-approved environment. Save time and resources with BostonGene’s streamlined investigational process.